The biomarker analysis of ADJUVANT/CTONG1104 study reported that the MINERVA score, which is calculated using five potential biomarkers of DFS (RB1 alteration, NKX2‐1 copy number gain, CDK4 copy number gain, TP53 exon4/5 missense alterations, and MYC copy number gain) identified by comprehensive genomic profiling, could be used to categorize resected EGFR‐mutated NSCLC into three subgroups by efficacy of adjuvant therapy (highly TKI‐preferable, TKI‐preferable, and chemotherapy‐preferable groups) [25]. This evidence concerns the gene RB1 and non-small cell lung carcinoma.